NCT05941897View on ClinicalTrials.gov

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

July 29, 2024

Study Completion Date

January 1, 2027

Conditions
Advanced or Metastatic NSCLC
Interventions
DRUG

Ceralasertib

Participants will receive ceralasertib oral tablets.

DRUG

Durvalumab

Participants will receive durvalumab as an intravenous infusion

Trial Locations (8)

111123

Research Site, Moscow

115478

Research Site, Moscow

115533

Research Site, Moscow

125284

Research Site, Moscow

143423

Research Site, Moscow

197758

Research Site, Saint Petersburg

198255

Research Site, Saint Petersburg

603126

Research Site, Nizhny Novgorod

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY